Pay in 4 interest-free payments of $5.00 Learn more
Ships within 48 hours · Estimated delivery Aug 5 - Aug 10
No changes were made to the endpoints for the comparison of tirzepatide versus dulaglutide in the expanded population because we observed high concordance with SURPASS-CVOT estimates in the primary composite endpoint as well as mortality in the benchmarking study
Factors such as overall health, body mass index (BMI), existing health conditions, and past weight loss attempts are taken into account
This knowledge facilitates informed decision-making and helps in tailoring treatment plans to meet individual needs while minimizing adverse effects
This increased our ability to detect gene expression differences
In an additional, 30-week placebo-controlled, study of patients with type 2 diabetes inadequately controlled with metformin comparing the maintenance of sitagliptin 100 mg versus withdrawal of sitagliptin when initiating basal insulin therapy, the event rate and incidence of documented symptomatic hypoglycemia (blood glucose measurement 70 mg/dL) did not differ between the sitagliptin and placebo groups
2025;16 doi: 10.1016/j.obpill.2025.100202
US$ 21.86
US$ 24.58
US$ 24.70
US$ 24.32
US$ 21.26
US$ 20.85
